[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Macrogenics (MGNX)

Macrogenics (MGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
MacroGenics: Q1 Earnings Snapshot

MacroGenics: Q1 Earnings Snapshot

MGNX : 4.46 (unch)
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

Manufacturing operations divestiture sharpens focus on core capabilities in novel drug discovery and development Manufacturing divestiture and expanded monetization of ZYNYZ royalty anticipated to provide...

MGNX : 4.46 (unch)
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals

•MacroGenics to receive $122.5 million upfront payment from Bora upon closing •Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora ROCKVILLE, MD,...

MGNX : 4.46 (unch)
MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement

ROCKVILLE, MD, May 04, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment...

MGNX : 4.46 (unch)
FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study

• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers   • On track to provide mid-2026 program update  ROCKVILLE, MD, April 08, 2026 (GLOBE NEWSWIRE) -- MacroGenics,...

MGNX : 4.46 (unch)
MacroGenics: Q4 Earnings Snapshot

MacroGenics: Q4 Earnings Snapshot

MGNX : 4.46 (unch)
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures

Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026 Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026 Lorigerlimab Phase 2 LINNET study update in mid-2026 IND submission for...

MGNX : 4.46 (unch)
MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,...

MGNX : 4.46 (unch)
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial

ROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment...

MGNX : 4.46 (unch)

Barchart Exclusives

Cerebras Just Got Fast-Tracked Into the S&P 500. Here’s What It Means for Investors
Cerebras jumps from IPO hype to S&P inclusion, turning early momentum into a forced buying event for index funds. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.